Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Development of New Medicines for Memory Impairment

17.01.2012
Using a novel approach, research scientists of the University of Basel will develop drugs for memory impairment together with the Lausanne based biopharmaceutical company AC Immune. This project is supported by the Commission for Technology and Innovation (CTI) of the Swiss Federal Department of Economic Affairs.

Memory problems are the main symptom of Alzheimer's Disease, but do also occur in many other neuropsychiatric disorders, such as in schizophrenia or depression. Today no satisfactory treatment options for memory impairment are available. The neuroscientists Dominique de Quervain and Andreas Papassotiropoulos of the University of Basel have been working on the characterization of the neurobiological and molecular basis of human memory for several years.

By applying genome-wide studies of large groups of healthy volunteers, they were able to identify important metabolic processes in human memory. The results of those studies provide the researchers with valuable information for the selection of possible targets for potential drugs against memory impairment. Both the molecular genetic studies and clinical trials are being conducted at the Division of Cognitive Neuroscience and the Division of Molecular Neuroscience of the University of Basel.

The Basel researchers use the large-scale information obtained in these studies to develop new medicines for memory impairment. To achieve this goal, the scientists have launched a collaboration with AC Immune. Led by Andrea Pfeifer, the biopharmaceutical company is a leader in Alzheimer´s Disease drug development and will bring its extensive knowledge to the collaboration.

The partner project "Human genetics-driven discovery of memory-modulating drugs" will start in March 2012. Three clinical studies are being supported through a grant of the CTI (Commission of Technology and Innovation) for three years.

For further information please contact:

Prof. Dr. Dominique de Quervain, Director of the Division of Cognitive Neuroscience, University Basel: dominique.dequervain@unibas.ch, Phone: +41 61 267 02 37

Prof. Dr. Andreas Papassotiropoulos, Director of the Division of Molecular Neuroscience, University Basel: andreas.papas@unibas.ch, Phone: +41 61 267 05 99

Prof. Andrea Pfeifer, CEO, AC Immune, Lausanne: andrea.pfeifer@acimmune.com, Phone: +41 21 693 91 34

Reto Caluori | Universität Basel
Further information:
http://www.unibas.ch

More articles from Health and Medicine:

nachricht Tracking movement of immune cells identifies key first steps in inflammatory arthritis
23.01.2017 | Massachusetts General Hospital

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Tracking movement of immune cells identifies key first steps in inflammatory arthritis

23.01.2017 | Health and Medicine

Electrocatalysis can advance green transition

23.01.2017 | Physics and Astronomy

New technology for mass-production of complex molded composite components

23.01.2017 | Process Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>